The ISPOR 2024 conference in Atlanta is themed “HEOR: A Transformative Force for Whole Health”. Will this advocated, holistic approach to HEOR, which is conceptually not new, be reflected in future drug pricing? In strategic forecasting, pricing and market access are key parameters. The Inflation Reduction Act has dominated the headlines on this topic since […]
We are almost one year on from ephmra’s 2023 annual conference when we were told that in the future, on average, AI will free up 37% of our time. For many this was a wake-up call at the time but one year later in Berlin, there is still a sentiment that it cannot yet be […]
Unlike 2022, luckily our Christmas lunch gathering has not been affected by any train or air travel strike action this year. So some of the people who make up groupH in Europe came together at the Zetter Townhouse for a couple of hours. Special thanks to our cello player Garwin Lynnell for not only a […]
Dear clients and colleagues, As another year draws to a close, it is not only friends, colleagues and family who have been sitting at work and dinner tables this year, but also a new visitor called AI. We hope you like the illustration on our Christmas card and that meeting AI is the ‘beginning of […]
Wednesday, 29 November 2023 at 16:00 UK (17:00 CET) Register here The Inflation-Reduction-Act (IRA) from 2022 is meant to curb US drug pricing for Medicare without directly impacting on the idea of free-pricing, which seems to be a principle very sacrosanct to the US market as a whole. Will the IRA achieve its objectives? How […]
On Friday 15th September, the groupH core team and local associates met in London for an end-of-summer social get together. At our dinner in Notting Hill, we celebrated togetherness, successfully completed projects, catching up on personal news and the fact that luck was on our side with glorious late-summer weather throughout the day.
Friday, 27 October 2023 at 13:00 UK (14:00 CET) Register here As a student already, Fritz Meyer has been interested in quantitative marketing, economics and epistemology. Forecasting projects have always been fascinating to Fritz, as forecasts have consequences. Every forecast is different for him based on the concrete business question. During his more than 20 […]
groupH’s discussion on TPP Development and Indication Prioritization took place at the NPP Summit Boston on October 16, 2023. Erik Holzinger and Iain Clark talked through 2 project case studies focusing on pre-clinical or early-stage clinical stage by sharing client views on project timing and project learnings. Please click on the here to view document. […]
groupH has analysed what is known about the Inflation Reduction Act (IRA) of 2022, which constitutes a major legislative effort to address drug pricing and Medicare expenditure. We developed a simple easy-to-use model, which assesses the risk of any of the three parts of the IRA applying to a product that is either already on […]
groupH will talk through 2 project case studies focusing on TPP Development and Indication Prioritization for Biotech companies at pre-clinical or early-stage clinical stage. The talk is aimed at individuals in commercial and non-commercial roles who have to manage uncertainty when aligning on overall scientific and commercial strategy. We will discuss a recent, real-world project […]
